PINK - New Tech Is Transforming Healthcare

2023-08-11 01:45:00 ET

Summary

• The U.S. healthcare system remains a global outlier in both innovation and cost.
• The U.S. spends twice as much per capita on healthcare versus its developed-country peers yet life expectancy is lower by 6.3 years.
• Healthcare companies continue to develop new technologies and seek new ways to improve patient outcomes and reduce overall cost.

By Kelly M. McMahon

The U.S. healthcare system remains a global outlier in both innovation and cost.

The U.S. healthcare system is both complex and expensive. The U.S. spends twice as much per capita on healthcare versus its developed-country peers yet life expectancy is lower by 6.3 years ¹ (in part due to a lack of pricing transparency, a mix of private and government payer systems, and an aging population).

Meanwhile, healthcare companies continue to develop new technologies and seek new ways to improve patient outcomes and reduce overall cost - efforts that, we believe, present potentially attractive opportunities for long-term investors.

Some key areas, in our view, that benefit from these trends include:

• Telehealth. Virtual delivery of basic healthcare services removes barriers to entry, especially for those in rural areas or with transportation issues, thereby increasing convenience and expanding access to care.
• Artificial Intelligence ((AI)). By identifying patterns in vast amounts of clinical data, groundbreaking generative AI models have the potential to accelerate a range of activities, such as diagnosis, treatment planning and drug discovery.
• Gene Therapy. These technologies can deliver genetic material into cells to correct or replace defective genes, potentially treating a wide range of diseases, including cancer, inherited disorders, and infectious diseases.
• Therapeutics. While the upfront costs for certain drugs can be steep, these treatments have the potential to treat chronic conditions and reduce costlier interventions, such as hospital visits. GLP-1 medicines ² , for example, can combat diabetes and obesity by mimicking the body’s natural GLP-1 hormone, which stimulates the release of insulin, in turn slowing the rate of digestion and suppressing appetite. While still in the early stages, weight-loss drugs have the potential to improve health outcomes and lower costs by reducing the risk of chronic conditions such as heart disease, stroke and kidney disease.

We believe new technological innovations and others are transforming the US healthcare landscape, making healthcare more accessible, personalized and effective.

As these innovative areas of healthcare continue to evolve, we continue to monitor and remain optimistic about the entrepreneurial spirit leading to better outcomes for patients and payers alike.

Source: (1) Peterson Center On Healthcare; (2) This acronym stands for Glucagon-like peptide-1

This material is provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice. This material is general in nature and is not directed to any category of investors and should not be regarded as individualized, a recommendation, investment advice or a suggestion to engage in or refrain from any investment-related course of action. Investment decisions and the appropriateness of this material should be made based on an investor's individual objectives and circumstances and in consultation with his or her advisors. Information is obtained from sources deemed reliable, but there is no representation or warranty as to its accuracy, completeness or reliability. All information is current as of the date of this material and is subject to change without notice. The firm, its employees and advisory accounts may hold positions of any companies discussed. Any views or opinions expressed may not reflect those of the firm as a whole. Neuberger Berman products and services may not be available in all jurisdictions or to all client types. This material may include estimates, outlooks, projections and other “forward-looking statements.” Due to a variety of factors, actual events or market behavior may differ significantly from any views expressed.

This material is not intended as a formal research report and should not be relied upon as a basis for making an investment decision. The firm, its employees and advisory accounts may hold positions of any companies discussed. Specific securities identified and described do not represent all of the securities purchased, sold or recommended for advisory clients. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable.

Investing entails risks, including possible loss of principal. Investments in hedge funds and private equity are speculative and involve a higher degree of risk than more traditional investments. Investments in hedge funds and private equity are intended for sophisticated investors only. Indexes are unmanaged and are not available for direct investment. Past performance is no guarantee of future results.

This material is being issued on a limited basis through various global subsidiaries and affiliates of Neuberger Berman Group LLC. Please visit www.nb.com/disclosure-global-communications for the specific entities and jurisdictional limitations and restrictions.

The “Neuberger Berman” name and logo are registered service marks of Neuberger Berman Group LLC.

© 2009-2023 Neuberger Berman Group LLC. All rights reserved.

Original Post

Editor's Note: The summary bullets for this article were chosen by Seeking Alpha editors.

For further details see: